Limited stage grade 3 follicular lymphoma patients can experience favorable outcomes with combined modality therapy

Zeina Ayoub; Therese Andraos; Sarah A. Milgrom; Chelsea C. Pinnix; Bouthaina S. Dabaja; Sweet Ping Ng; Jillian R. Gunther; Joseph D. Khoury; Nathan H. Fowler; Satva S. Neelapu; Felipe Samaniego; Luis E. Fayad; Loretta J. Nastoupil

doi:10.1080/10428194.2019.1597081

Limited stage grade 3 follicular lymphoma patients can experience favorable outcomes with combined modality therapy

Zeina Ayoub, Therese Andraos, Sarah A. Milgrom, Chelsea C. Pinnix, Bouthaina S. Dabaja, Sweet Ping Ng, Jillian R. Gunther, Joseph D. Khoury, Nathan H. Fowler, Satva S. Neelapu, Felipe Samaniego, Luis E. Fayad, Loretta J. Nastoupil

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Controversy exists regarding the optimal management of limited stage grade 3 follicular lymphoma (FL3). We assessed the treatment outcomes of 190 consecutive patients with stage I-II FL. Fifty two patients had FL3 disease, in whom the median age was 55 years. At a median follow-up of 65 months, 5-year progression-free survival (PFS) and overall survival (OS) rates were 76.6% and 87.6%, respectively. Patients receiving systemic therapy followed by radiation therapy (RT) had a significantly better PFS (p=.003) than those treated with RT alone, but similar OS (p =.476). Patients treated with RT had 100% local control. Compared to 132 patients with grade 1–2 FL, those with FL3 had similar PFS (p =.493) and OS (p =.330). Patients with FL3 can experience favorable outcomes when treated with a combination of systemic therapy and RT, comparable to low grade FL.

Original language	English (US)
Pages (from-to)	2432-2440
Number of pages	9
Journal	Leukemia and Lymphoma
Volume	60
Issue number	10
DOIs	https://doi.org/10.1080/10428194.2019.1597081
State	Published - Aug 24 2019
Externally published	Yes

Keywords

Follicular lymphoma
chemotherapy
radiation
survival

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1080/10428194.2019.1597081

Cite this

Ayoub, Z., Andraos, T., Milgrom, S. A., Pinnix, C. C., Dabaja, B. S., Ng, S. P., Gunther, J. R., Khoury, J. D., Fowler, N. H., Neelapu, S. S., Samaniego, F., Fayad, L. E., & Nastoupil, L. J. (2019). Limited stage grade 3 follicular lymphoma patients can experience favorable outcomes with combined modality therapy. Leukemia and Lymphoma, 60(10), 2432-2440. https://doi.org/10.1080/10428194.2019.1597081

Ayoub, Z, Andraos, T, Milgrom, SA, Pinnix, CC, Dabaja, BS, Ng, SP, Gunther, JR, Khoury, JD, Fowler, NH, Neelapu, SS, Samaniego, F, Fayad, LE & Nastoupil, LJ 2019, 'Limited stage grade 3 follicular lymphoma patients can experience favorable outcomes with combined modality therapy', Leukemia and Lymphoma, vol. 60, no. 10, pp. 2432-2440. https://doi.org/10.1080/10428194.2019.1597081

@article{633c8582c6f14fd8af1b656e1197e5e1,

title = "Limited stage grade 3 follicular lymphoma patients can experience favorable outcomes with combined modality therapy",

abstract = "Controversy exists regarding the optimal management of limited stage grade 3 follicular lymphoma (FL3). We assessed the treatment outcomes of 190 consecutive patients with stage I-II FL. Fifty two patients had FL3 disease, in whom the median age was 55 years. At a median follow-up of 65 months, 5-year progression-free survival (PFS) and overall survival (OS) rates were 76.6% and 87.6%, respectively. Patients receiving systemic therapy followed by radiation therapy (RT) had a significantly better PFS (p=.003) than those treated with RT alone, but similar OS (p =.476). Patients treated with RT had 100% local control. Compared to 132 patients with grade 1–2 FL, those with FL3 had similar PFS (p =.493) and OS (p =.330). Patients with FL3 can experience favorable outcomes when treated with a combination of systemic therapy and RT, comparable to low grade FL.",

keywords = "Follicular lymphoma, chemotherapy, radiation, survival",

author = "Zeina Ayoub and Therese Andraos and Milgrom, {Sarah A.} and Pinnix, {Chelsea C.} and Dabaja, {Bouthaina S.} and Ng, {Sweet Ping} and Gunther, {Jillian R.} and Khoury, {Joseph D.} and Fowler, {Nathan H.} and Neelapu, {Satva S.} and Felipe Samaniego and Fayad, {Luis E.} and Nastoupil, {Loretta J.}",

note = "Publisher Copyright: {\textcopyright} 2019, {\textcopyright} 2019 Informa UK Limited, trading as Taylor & Francis Group.",

year = "2019",

month = aug,

day = "24",

doi = "10.1080/10428194.2019.1597081",

language = "English (US)",

volume = "60",

pages = "2432--2440",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "10",

}

TY - JOUR

T1 - Limited stage grade 3 follicular lymphoma patients can experience favorable outcomes with combined modality therapy

AU - Ayoub, Zeina

AU - Andraos, Therese

AU - Milgrom, Sarah A.

AU - Pinnix, Chelsea C.

AU - Dabaja, Bouthaina S.

AU - Ng, Sweet Ping

AU - Gunther, Jillian R.

AU - Khoury, Joseph D.

AU - Fowler, Nathan H.

AU - Neelapu, Satva S.

AU - Samaniego, Felipe

AU - Fayad, Luis E.

AU - Nastoupil, Loretta J.

PY - 2019/8/24

Y1 - 2019/8/24

N2 - Controversy exists regarding the optimal management of limited stage grade 3 follicular lymphoma (FL3). We assessed the treatment outcomes of 190 consecutive patients with stage I-II FL. Fifty two patients had FL3 disease, in whom the median age was 55 years. At a median follow-up of 65 months, 5-year progression-free survival (PFS) and overall survival (OS) rates were 76.6% and 87.6%, respectively. Patients receiving systemic therapy followed by radiation therapy (RT) had a significantly better PFS (p=.003) than those treated with RT alone, but similar OS (p =.476). Patients treated with RT had 100% local control. Compared to 132 patients with grade 1–2 FL, those with FL3 had similar PFS (p =.493) and OS (p =.330). Patients with FL3 can experience favorable outcomes when treated with a combination of systemic therapy and RT, comparable to low grade FL.

AB - Controversy exists regarding the optimal management of limited stage grade 3 follicular lymphoma (FL3). We assessed the treatment outcomes of 190 consecutive patients with stage I-II FL. Fifty two patients had FL3 disease, in whom the median age was 55 years. At a median follow-up of 65 months, 5-year progression-free survival (PFS) and overall survival (OS) rates were 76.6% and 87.6%, respectively. Patients receiving systemic therapy followed by radiation therapy (RT) had a significantly better PFS (p=.003) than those treated with RT alone, but similar OS (p =.476). Patients treated with RT had 100% local control. Compared to 132 patients with grade 1–2 FL, those with FL3 had similar PFS (p =.493) and OS (p =.330). Patients with FL3 can experience favorable outcomes when treated with a combination of systemic therapy and RT, comparable to low grade FL.

KW - Follicular lymphoma

KW - chemotherapy

KW - radiation

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=85063859684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063859684&partnerID=8YFLogxK

U2 - 10.1080/10428194.2019.1597081

DO - 10.1080/10428194.2019.1597081

M3 - Article

C2 - 30942648

AN - SCOPUS:85063859684

SN - 1042-8194

VL - 60

SP - 2432

EP - 2440

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 10

ER -

Limited stage grade 3 follicular lymphoma patients can experience favorable outcomes with combined modality therapy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this